Fluvastatin

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate.

12.1 Mechanism of Action Fluvastatin sodium is a competitive inhibitor of HMG-CoA reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of sterols, including cholesterol. The inhibition of cholesterol biosynthesis reduces the cholesterol in hepatic cells, which stimulates the synthesis of LDL receptors and thereby increases the uptake of LDL particles. The end result of these biochemical processes is a reduction of the plasma cholesterol concentration.

With Biphasic clearance with 8–20 hr terminal t½ under Fluvastatin maintenance residence kinetics and ~24% systemic bioavailability (Fluvastatin) bioavailability, Fluvastatin undergoes hepatic enzymatic processing and renal clearance proportional to creatinine clearance (fluvastatin) and establishes therapeutic activity over initial pharmacodynamic onset within 1–2 hrs (peak cmax) for fluvastatin.

Standard adult regimens span 40 mg/1 Capsule, 20 mg/1 Capsule, 20mg Capsule, 40mg Capsule. Prescribers screen specifically against prior anaphylaxis, angioedema, or severe hypersensitivity to fluvastatin or fluvastatin excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2025-10-21 fluvastatin spl, while community micro-logs most frequently note nausea (12.2% of reports), headache (10.8% of reports), dizziness (5.1% of reports).